The advent of potent, pan-genotypic all-oral direct-acting antiviral (DAA) regimens necessitates a critical examination of the immediate application of PEG-IFN, ribavirin and DAA regimens in patients with chronic hepatitis C. This comprehensive Review outlines some of the conundrums facing physicians and summarizes current and pending treatment options for patients with hepatitis C.
- Paul M. Trembling
- Sudeep Tanwar
- Geoffrey M. Dusheiko
